An alternative to this immunological mechanism for the biomarker changes could be amyloid deposits linked to premorbid hypoxic or ischemic brain damage and upregulation of BACE1 gene expression, which have been identified in patients who died after severe COVID-19 (ref. 50). The gene discussed is BACE1; the disease is COVID-19.